沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭的临床疗效  

Clinical efficacy of sacubitril valsartan sodium tablets combined with metoprolol succinate extended-release tablets in treatment of chronic heart failure

作　　者：陈颖[1] 顾纪新 王蒙[1] 付强 Chen Ying;Gu Jixin;Wang Meng;Fu Qiang(Department of Cardiology and Nephrology,No.965 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army,Jilin,Jilin 132011,China;Health Team of Unit 96782 of the Chinese People's Liberation Army,Putian,Fujian 351100,China)

机构地区：[1]中国人民解放军联勤保障部队第九六五医院心肾内科,吉林132011 [2]中国人民解放军96782部队卫生队,福建莆田351100

出　　处：《齐齐哈尔医学院学报》2024年第20期1931-1935,共5页Journal of Qiqihar Medical University

摘　　要：目的探讨沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片在慢性心力衰竭中的临床应用价值。方法选择2021年3月—2024年3月本院收治的慢性心力衰竭患者120例作为研究对象,随机数表法分为对照组(60例,给予口服琥珀酸美托洛尔缓释片治疗)与观察组(60例,在对照组基础上联合沙库巴曲缬沙坦钠片治疗)两组。两组均持续治疗12周后评估疗效,比较两组临床疗效、心功能指标、炎症因子指标、神经内分泌激素水平和药物不良反应发生情况。结果治疗后观察组总有效率[90.00%(54/60)]高于对照组[75.00%(45/60)](χ^(2)=4.675,P<0.05)。治疗后两组左室射血分数(LVEF)较治疗前升高(P<0.05),左室舒张末期内径(LVEDD)、N末端B型利钠肽原(NT-ProBNP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、去甲肾上腺素(NE)、醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)水平较治疗前下降(P<0.05),观察组LVEF高于对照组(P<0.05),LVEDD、NT-ProBNP、IL-6、TNF-α、hs-CRP、NE、ALD、AngⅡ水平则低于对照组(P<0.05)。两组治疗期间均有恶心、腹胀、乏力、头晕等少量不良反应,发生率比较无明显差异(P>0.05)。结论沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭疗效确切,可改善患者心功能,减轻炎症反应,抑制神经内分泌激素活性,优于单用琥珀酸美托洛尔,且安全性较高。Objective To investigate the clinical application value of sacubitril valsartan sodium tablets combined with metoprolol succinate extended-release tablets in treating chronic heart failure.Methods A total of 120 patients with chronic heart failure admitted to our hospital from March 2021 to March 2024 were enrolled as study subjects.They were randomly divided into a control group(60 cases,treated with oral metoprolol succinate extended-release tablets)and an observation group(60 cases,treated with sacubitril valsartan sodium tablets in addition to the control group's treatment)using the random number table method.The clinical therapeutic efficacy of the two groups was evaluated after 12 weeks of continuous treatment,and the clinical efficacy,cardiac function indexes,inflammatory factor indexes,neuroendocrine hormone levels,and the occurrence of adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group[90.00%(54/60)]was higher than that of the control group[75.00%(45/60)]after treatment(χ^(2)=4.675,P<0.05).After treatment,the left ventricular ejection fraction(LVEF)in both groups increased compared to before treatment(P<0.05).The left ventricular end-diastolic diameter(LVEDD),N-terminal pro-B-type natriuretic peptide(NT-ProBNP),interleukin-6(IL-6),tumor necrosis factor-alpha(TNF-α),high-sensitivity C-reactive protein(hs-CRP),norepinephrine(NE),aldosterone(ALD),and angiotensinⅡ(Ang II)levels decreased compared to before treatment(P<0.05).In the observation group,LVEF was higher than that in the control group(P<0.05),while the levels of LVEDD,NT-ProBNP,IL-6,TNF-α,hs-CRP,NE,ALD,and Ang II were lower than those in the control group(P<0.05).A few adverse reactions such as nausea,abdominal distension,fatigue,dizziness,etc.,were observed in both groups during the treatment period,and there were no significant differences in the incidence rates between the two groups(P>0.05).Conclusions The combination of sacubitril valsartan sodium tablets with metoprolol s

关 键 词：慢性心力衰竭 沙库巴曲缬沙坦钠片 琥珀酸美托洛尔缓释片 临床疗效 

分 类 号：R541[医药卫生—心血管疾病]